Spyre Therapeutics Files 8-K on Financials

TL;DR

Spyre Therapeutics (SPYR) filed an 8-K on Oct 14, 2025, updating its financial condition.

AI Summary

Spyre Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on its results of operations and financial condition. The company, formerly known as Aeglea BioTherapeutics, Inc. until March 11, 2015, is incorporated in Delaware and headquartered in Waltham, MA.

Why It Matters

This filing provides an update on Spyre Therapeutics' financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing providing standard corporate information and financial updates, not indicating any immediate material changes or risks.

Key Players & Entities

• Spyre Therapeutics, Inc. (company) — Registrant
• Aeglea BioTherapeutics, Inc. (company) — Former Company Name
• October 14, 2025 (date) — Date of Report
• Waltham, MA (location) — Principal Executive Offices
• 02453 (zip_code) — Principal Executive Offices Zip Code

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 Par Value Per Share SYRE The Nasdaq
• $486.2 million — cts to report that it had approximately $486.2 million of cash, cash equivalents and marketabl

Filing Documents

• d85106d8k.htm (8-K) — 28KB
• 0001193125-25-237904.txt ( ) — 144KB
• syre-20251014.xsd (EX-101.SCH) — 3KB
• syre-20251014_lab.xml (EX-101.LAB) — 18KB
• syre-20251014_pre.xml (EX-101.PRE) — 11KB
• d85106d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K, other than statements of historical fact are forward-looking statements. These forward-looking statements include statements regarding the Company's cash guidance. The words "believe," "may," "will," "potentially," "estimate," "continue," "anticipate," "predict," "target," "intend," "could," "would," "should," "project," "plan," "expect," the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited, the expected or potential impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policy, volatile market conditions, financial institution instability, as well as geopolitical instability, including the ongoing military conflicts between Ukraine and Russia, conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on the Company's operations; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact our business operations, including restricting international trade by the United States, China or other countries and the BIOSECURE Act or similar ac

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SPYRE THERAPEUTICS, INC. Date: October 14, 2025 By: /s/ Cameron Turtle Cameron Turtle Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR